Theramex Chooses IQVIA’s Orchestrated Customer Engagement

Leading women’s health company selects IQVIA’s OCE technology solution to transform engagement with healthcare professionals and improve the value of every client interaction

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--()--IQVIA™ (NYSE: IQV), a company dedicated to applying advanced analytics and technology in healthcare to help clients find better solutions for patients, and Theramex, an international pharmaceutical company dedicated to women’s health, today announced a global technology collaboration to integrate IQVIA’s market-leading Orchestrated Customer Engagement (OCE) platform into Theramex’s European commercial operations.

OCE seamlessly connects marketing, sales and other functions to generate a comprehensive, intelligence-driven customer engagement system. Life sciences clients and their customers immediately benefit from the faster removal of internal silos, more accurate decision-making through predictive analytics and machine learning, and optimized performance across the enterprise.

“As a company dedicated to women’s health, Theramex is committed to enhancing its client engagement model to provide better access to our expanding portfolio of products,” said Anish Mehta, chief executive officer, Theramex. “We are pleased to engage IQVIA as our technology partner to support our bold growth ambitions. OCE is breaking new ground in customer relationship management, and we are excited about how this innovative platform will advance our customer interactions.”

Under the terms of the agreement, Theramex will move its existing platforms to OCE in 2018 as it expands its women’s health portfolio. Theramex was formed following CVC Capital Partners’ February 2018 acquisition of Teva Pharmaceutical Industries’ international women’s health business.

“We are delighted Theramex has chosen to adopt this platform ahead of traditional customer relationship management solutions that offer limited flexibility and insight,” said Alistair Grenfell, president, North Europe, Middle East, Africa and South Asia, IQVIA. “OCE is a genuine evolution in the way pharmaceutical companies manage customer and stakeholder relationships, make better decisions, and improve productivity.

“Theramex will be able to take full advantage of OCE’s advanced analytics and machine learning to drive clearer understanding of its customers’ needs with simpler, easier work streams across the company.”

About Theramex

Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing innovative, effective and safe solutions that care for and support women as their healthcare needs change. For more information, visit www.theramex.com.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Click here to subscribe to Mobile Alerts for IQVIA.

Contacts

IQVIA
Media Relations:
Tor Constantino, +1-484-567-6732
tor.constantino@iqvia.com
or
Investor Relations:
Andrew Markwick, +1-973-257-7144
andrew.markwick@iqvia.com

Contacts

IQVIA
Media Relations:
Tor Constantino, +1-484-567-6732
tor.constantino@iqvia.com
or
Investor Relations:
Andrew Markwick, +1-973-257-7144
andrew.markwick@iqvia.com